Prelude Therapeutics Incorporated
PRLD
$3.36
$0.061.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.57% | 36.84% | 2.66% | -11.67% | 10.97% |
| Total Depreciation and Amortization | -1.65% | -1.85% | -0.46% | -11.04% | 20.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -26.01% | -30.80% | -7.24% | 33.76% | -41.65% |
| Change in Net Operating Assets | 1,543.16% | -448.04% | 110.75% | -260.39% | 559.49% |
| Cash from Operations | 220.95% | 26.69% | 23.83% | -65.02% | 24.00% |
| Capital Expenditure | -- | 100.00% | 57.45% | 11.32% | 15.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -250.51% | 247.38% | -81.46% | 180.70% | 105.36% |
| Cash from Investing | -250.51% | 247.98% | -81.47% | 181.16% | 106.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 65.81% | -2.65% | -2.03% |
| Issuance of Common Stock | -- | -100.00% | -- | -- | 121.43% |
| Repurchase of Common Stock | 0.00% | -150.00% | 60.00% | 28.57% | 46.15% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 498,980.00% | -113.51% | 123.13% | -370.59% | 74.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -158.54% | 244.46% | -152.23% | 1,974.25% | 108.03% |